Intended for licensed healthcare professionals located in the Republic of Ireland only.
Because Tomorrows Matters Today
Blue square
Experts tell the ICLUSIG story

since the initial approval of iclusig in europe in 2013, we have over 10 years of experience in treating patients with cml

Video intro icon
Click on the short videos below to see how far we’ve come and learn why the experts think you should consider switching eligible patients with CML* to ICLUSIG after one 2G TKI...
Watch video
Jane Apperley
Centre for Haematology
Hammersmith Hospital
Imperial College London
London, UK
ICLUSIG has been with you since 2013, proudly demonstrating fast, deep and durable responses as seen in the long-term follow-up of the PACE study1,2
Watch video
Gianantonio Rosti
IRCCS/SIRHHC Scientific Institute for Research, Hospitalization and Health Care ‘Dino Amadori’
Meldola (FC), Italy
The ELN CML Guidelines (2020) named ICLUSIG as the preferred treatment in patients with resistance to a 2G TKI without mutations, unless cardiovascular risk factors preclude its use3
Watch video
Jorge Cortes
Georgia Cancer Center
Augusta, GA, USA
Thanks to the recent response-based dosing study, OPTIC, there’s now clear evidence to induce, reduce and maintain ICLUSIG to manage your patients4,5
Induce response with 45 mg orally, once daily; reduce dose to 15 mg orally, once daily, upon achievement of ≤1% BCR::ABL1; maintain response with 15 mg orally, once daily.
ICLUSIG: COMMITMENT TO BUILDING PATIENTS' FUTURES
Adverse events should be reported. Reporting forms and information can be found at www.hpra.ie. Adverse events should also be reported to Incyte immediately by phoning the Toll-free phone number 1800-456-748.